Fate Therapeutics grants new hires 300,000 stock options, 87,000 restricted stock units
FATE•Fate Therapeutics granted options covering 300,000 shares to one new non-executive employee and restricted stock units covering 87,000 shares to two new non-executive employees on November 2, 2026.
1. Equity awards
Fate Therapeutics granted non-qualified stock options covering 300,000 shares to one newly hired non-executive employee on November 2, 2026. Restricted stock units covering 87,000 shares went to two newly hired non-executive employees, including the option recipient.
2. Vesting schedules
The options vest 25% on the grant’s first anniversary, with the remaining 75% vesting in approximately equal monthly installments over 36 months. The RSUs vest 25% on each grant anniversary over four years. All awards require continuous employment through each vesting date.
